INCIDENCE AND CHARACTERIZATION OF SECONDARY MYELODYSPLASTIC SYNDROME AND ACUTE MYELOGENOUS LEUKEMIA FOLLOWING HIGH-DOSE CHEMORADIOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR LYMPHOID MALIGNANCIES
INCIDENCE AND CHARACTERIZATION OF SECONDARY MYELODYSPLASTIC SYNDROME AND ACUTE MYELOGENOUS LEUKEMIA FOLLOWING HIGH-DOSE CHEMORADIOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR LYMPHOID MALIGNANCIES
复制标题
DOI：
10.1200/jco.1994.12.12.2527
复制
发表时间：
1994-12-01
影响因子：
45.3
通讯作者：
ARMITAGE, JO
中科院分区：
文献类型：
--
作者：
DARRINGTON, DL;VOSE, JM;ARMITAGE, JO
目的：分析自体骨髓移植（ABMT）或外周血干细胞移植（PSCT）后发生骨髓增生异常综合征（MDS）或急性髓性白血病（AML）的风险，并确定对无失败生存期（FFS）的影响。例接受ABMT或PSCT治疗霍奇金病（HD）和非霍奇金淋巴瘤（NHL）的患者在内布拉斯加大学医学中心对于那些谁继续发展MDS/AML的患者，选择对照组和病例对照组内的一个队列studyundertaking.Results：12例MDS或AML的中位数为44个月后ABMT/PSCT。HD和NHL患者MDS/AML的累积发病率（P =.42）和条件概率（P =.32）无统计学差异。年龄大于40岁时移植（P = 0.05）和接受全身照射（TBI）的方案（P = 0.06）是预测发展MDS/AML的NHL患者。结论：有一个MDS/AML的风险增加AMBT/PSCT淋巴系统恶性肿瘤。NHL患者在移植时年龄大于或等于40岁，并且接受TBI的风险最大。(C)1994年，美国临床肿瘤学会。
Purpose: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS).Patients and Methods: patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken.Results: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P =.42) and the conditional probability (P =.32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplant (P =.05) and receipt of a total-body irradiation (TBI)-containing regimen (P =.06) were predictive for developing MDS/AML in patients with NHL.Conclusion: There is an increased risk of MDS/AML following AMBT/PSCT for lymphoid malignancies. NHL patients age greater than or equal to 40 years at the time of transplant and who received TBI are at greatest risk. (C) 1994 by American Society of Clinical Oncology.